Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion

BTIG Research's Rating of Serina Therapeutics on 10/26/2026

On October 26, 2026, BTIG Research updated its outlook on Serina Therapeutics (NYSEAMERICAN:SER) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from BTIG Research

DateCompanyAction
10/26/2026
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Reiterated Rating
10/26/2026
Serina Therapeutics, Inc. stock logo
SER
Serina Therapeutics
Reiterated Rating
10/26/2026
McDonald's Corporation stock logo
MCD
McDonald's
Reiterated Rating
10/26/2026
Paycom Software, Inc. stock logo
PAYC
Paycom Software
Boost Price Target
10/26/2026
Paylocity Holding Corporation stock logo
PCTY
Paylocity
Boost Price Target
10/26/2026
Tempus AI, Inc. stock logo
TEM
Tempus AI
Reiterated Rating
More Ratings From BTIG Research